Diffuse Large B-cell Lymphoma

Diffuse Large B-cell Lymphoma Typical Presentation: Diffuse Large B-cell Lymphoma (DLBCL) is a type of non-Hodgkin’s lymphoma. The typical presentation of DLBCL includes:

• Enlarged lymph nodes, often painless
• B symptoms: Fever, night sweats, and unintended weight loss
• Fatigue and weakness
• Shortness of breath or chest pain (if lymphoma affects the mediastinal region)
• Abdominal pain or swelling (if lymphoma affects the abdominal region)
• Neurological symptoms (if lymphoma affects the central nervous system)

Etiology: The exact cause of DLBCL is unknown. However, certain risk factors have been associated with its development, such as older age, immunodeficiency (e.g., HIV infection), prior autoimmune diseases, exposure to certain viruses (Epstein-Barr virus), and genetic abnormalities. Common Differential Diagnosis: The common differential diagnoses for DLBCL include other types of non-Hodgkin’s lymphomas, Hodgkin’s lymphoma, other hematologic malignancies, and reactive lymphadenopathy. Typical Diagnostic Work-Up: The diagnostic work-up for DLBCL includes:

• Physical examination to assess lymph nodes and other affected areas.
• Blood tests: Complete blood count (CBC) to evaluate white blood cell (WBC) count, red blood cell (RBC) count, and platelet count. Elevated lactate dehydrogenase (LDH) levels may also be present.
• Biopsy of an affected lymph node or other involved tissue for histological analysis and immunophenotyping.
• Staging procedures such as computed tomography (CT) scans, positron emission tomography (PET) scans, bone marrow biopsy, and lumbar puncture (if central nervous system involvement is suspected).

Treatment Plan: The treatment plan for DLBCL depends on various factors including the stage of the disease, patient’s overall health status, and other individual characteristics. Treatment options may include:

• Chemotherapy: Combination chemotherapy regimens such as R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) are commonly used.
• Radiation therapy: In some cases, radiation therapy may be used to target specific areas of involvement.
• Immunotherapy: The addition of targeted therapies such as rituximab or other monoclonal antibodies may be considered.
• Stem cell transplant: In cases of relapsed or refractory disease, a stem cell transplant may be recommended.

Preventative Measures: As the cause of DLBCL is largely unknown, specific preventative measures are not available. However, maintaining a healthy lifestyle, managing underlying medical conditions, and reducing exposure to potential risk factors (e.g., viral infections) may help reduce the overall risk. Appropriate Referrals: Appropriate referrals for individuals with DLBCL may include:

• Hematologist or oncologist for specialized management and treatment.
• Radiation oncologist if radiation therapy is considered.
• Support groups or mental health professionals to address emotional and psychosocial needs.

Additional Information Important to the Geriatric Population: DLBCL can occur in individuals of any age group, including the geriatric population. However, geriatric patients may have unique considerations such as comorbidities, reduced organ function, and increased vulnerability to treatment-related side effects. Close monitoring of organ function, tailored treatment plans considering overall health status and potential drug interactions with other medications commonly used in older adults are important in this population. Comprehensive geriatric assessments may aid in determining the suitability of treatment options and optimizing supportive care in elderly patients with DLBCL. References:

1. Coiffier B. Diffuse large cell lymphoma. Curr Hematol Malig Rep. 2006;1(4):219-226.
2. Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375-2390.

Sample Answer